PIXITMEDIA
5.9.2022 16:34:37 CEST | Business Wire | Press release
pixitmedia1, a Kalray company, has announced today that pixstor™ and ngenea® (a shared storage and data orchestration solution) will be included in the content production area at the Amazon Web Services (AWS) stand (5.C80) at IBC 2022.
AWS will be showcasing a suite of end-to-end cloud production workflows, demonstrating how the industry’s leading tools for editing, compositing, finishing, grading and quality control (QC) can be used for full production in the cloud. These workflows will be supported by pixitmedia’s flagship products, pixstor and ngenea, software-defined storage and orchestration software.
This follows the announcement that pixitmedia has been accepted into the AWS Independent Software Vendor (ISV) Accelerate Program, a co-sell program for AWS Partners who provide software solutions that run on or integrate with AWS.
Offline editorial, visual effects (VFX) and color grading work is not only possible in the cloud, but can deliver huge and tangible benefits in performance, collaboration, scalability, and cost efficiencies for producers.
At IBC stand 5.C80, AWS will demonstrate the media creation lifecycle in five stages. Live camera footage will be ingested to a cloud collaborative environment using dailies platform Moxion. That footage will be edited in Adobe® Premiere® Pro and conformed in Flame®, Autodesk®'s finishing and VFX solution. A fourth stage will demonstrate FilmLight Baselight performing the color grade, and finally, the content will pass through Colorfront Streaming and Broker Service for QC, which also reads directly from Amazon S3.
The high-resolution, uncompressed 4K media for all five stages of the production process will be edited in place on the powerful media-centric storage infrastructure powered by pixstor and ngenea, with 10-bit uncompressed video streamed from applications running in the cloud to the stand. It will use the latest AWS Cloud Digital Interface (AWS CDI), NewTek Network Device Interface (NDI), and Colorfront Streaming and Broker Service technology, over a secure internet connection to an Amazon VPC. Amazon EC2 compute, Amazon Elastic Block Store and Amazon S3 storage underpin the entire pixstor and ngenea solution.
Ben Leaver, EVP of Business Development and Co-Founder of pixitmedia explains:
“We’re looking forward to being featured in the AWS stand at IBC to showcase our storage and data orchestration platform to the Media & Entertainment industry. Together with AWS and industry-standard software providers, we will demonstrate that high-end editorial, VFX and color grading work is possible in the cloud today. We are providing our customers with ease of use, guaranteed performance, greater collaboration and seamless workflows in the cloud.”
pixitmedia is a global member of the AWS Partner Network (APN) and an industry facilitator of cloud-enabled production workflows. pixstor offers AWS customers an agile storage environment that guarantees adaptability and performance. Coupled with the power of pixitmedia’s ngenea, it quickly and securely transports data to and from globally distributed cloud, object storage, and traditional network attached storage (NAS).
To learn more about pixitmedia at IBC 2022, click here
About pixitmedia
pixitmedia is a Kalray company (Euronext, ALKAL), a leading provider of hardware and software technologies and solutions for high-performance, data centric computing markets, from cloud to edge. pixitmedia and Kalray share a common vision and a complementary value proposition in both software and hardware to address today’s and tomorrow’s data-intensive world with solutions for a more intelligent, effective, energy-wise and user-friendly data-driven world.
pixitmedia facilitates seamless collaboration to enable the power of ideas. Our award-winning purpose-built, software-defined storage and data solutions simplify the flow of data to connect an increasingly complex world. Our aim is to deliver beyond expectations throughout all areas of our operation. We devise optimized solutions that give customers both choice and freedom, our restless innovation constantly pushes boundaries and the unrivalled care and knowledge of our team ensure optimum performance and value. Customer success is at the heart of our business, we have technical specialists and a unique, dedicated lab facility to guarantee the effectiveness of our solutions.
For more information, please visit: https://www.pixitmedia.com or email: marketing@pixitmedia.com
About Kalray
Kalray (Euronext Growth Paris - ALKAL) is a leading provider of hardware and software technologies and solutions for high-performance,
data-centric computing markets, from cloud to edge. Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and data center infrastructures.
Kalray’s offerings include its unique patented DPU (Data Processing Unit) processors and acceleration cards, as well as its leading-edge
software-defined storage and data management offers. Individually or combined, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors and Bpifrance, Kalray is dedicated through technology, expertise and passion to offer more: more for a smart world, more for the planet, more for customers and developers. https://www.kalrayinc.com
1 pixitmedia is the dedicated branch for Media & Entertainment markets of arcapix Holdings Ltd, acquired by Kalray. See press release on March 3, 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220905005287/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom